Some augmentation strategies improve outcome but increase discontinuation in adults with treatment-resistant depression

Affiliations

Comment

Chittaranjan Andrade. Evid Based Ment Health. 2016 May.

. 2016 May;19(2):e7.

doi: 10.1136/eb-2015-102146.

¹ Department of Psychopharmacology, National Institute of Mental Health and Neurosciences, Bangalore, India; andradec@gmail.com.

No abstract available

Comment on

Comparative efficacy, acceptability, and tolerability of augmentation agents in treatment-resistant depression: systematic review and network meta-analysis.
Zhou X, Ravindran AV, Qin B, Del Giovane C, Li Q, Bauer M, Liu Y, Fang Y, da Silva T, Zhang Y, Fang L, Wang X, Xie P. Zhou X, et al. J Clin Psychiatry. 2015 Apr;76(4):e487-98. doi: 10.4088/JCP.14r09204. J Clin Psychiatry. 2015. PMID: 25919841

1. Malhi GS, Bassett D, Boyce P, et al. . Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. Aust N Z J Psychiatry 2015;49:1087–206. 10.1177/0004867415617657 - DOI - PubMed
1. Mavridis D, Giannatsi M, Cipriani A, et al. . A primer on network meta-analysis with emphasis on mental health. Evid Based Ment Health 2015;18:40–6. 10.1136/eb-2015-102088 - DOI - PMC - PubMed
1. McKeage K. Adjunctive brexpiprazole: a review in major depressive disorder. CNS Drugs 2016;30:91–9. 10.1007/s40263-016-0320-0 - DOI - PubMed